title: Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.
abstract: Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative. We conducted a study of intensive single AHCT using tandem chemo-mobilization with CY and etoposide followed by high-dose conditioning with melphalan 200 mg/m(2) plus carmustine 15 mg/kg. One hundred and eighteen patients in first consolidation (CON1) and 58 patients in relapse (REL) were transplanted using this intensified approach. Disease response improved from 32% very good PR (VGPR)+CR pre-mobilization to 76% VGPR+CR post transplant in CON1. With a median follow-up of 4.7 years, the median EFS was 2.8 years, and the median OS was 5.1 years in CON1. OS from time of transplant was significantly shorter for REL (3.4 years) compared with CON1 (5.1 years; P=0.02). However, OS from time of diagnosis was similar in REL (6.1 years) and CON1 (6.0 years; P=0.80). The 100-day non-relapse mortality in the CON1 and REL groups was 0% and 7%, respectively. In summary, intensified single AHCT with tandem chemo-mobilization and augmented high-dose therapy is feasible in multiple myeloma and leads to high-quality response rates.
authors: Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR 97239, USA. chenan@ohsu.edu
authors: A I
authors: AI
authors: Chen
authors: R S
authors: RS
authors: Negrin
authors: A
authors: A
authors: McMillan
authors: J A
authors: JA
authors: Shizuru
authors: L J
authors: LJ
authors: Johnston
authors: R
authors: R
authors: Lowsky
authors: D B
authors: DB
authors: Miklos
authors: S
authors: S
authors: Arai
authors: W-K
authors: WK
authors: Weng
authors: G G
authors: GG
authors: Laport
authors: K
authors: K
authors: Stockerl-Goldstein
references: Blood. 2003 Nov 1;102(9):3447-54
references: 12855572
references: N Engl J Med. 1996 Jul 11;335(2):91-7
references: 8649495
references: Blood. 2008 Mar 1;111(5):2516-20
references: 17975015
references: Br J Haematol. 2007 Jul;138(2):176-85
references: 17593024
references: J Natl Cancer Inst. 1993 Apr 21;85(8):640-7
references: 8468721
references: Blood. 2002 Feb 1;99(3):731-5
references: 11806971
references: J Clin Oncol. 2008 Jan 20;26(3):480-92
references: 18056678
references: Blood. 1999 Jan 1;93(1):55-65
references: 9864146
references: Leukemia. 2006 Sep;20(9):1467-73
references: 16855634
references: J Clin Oncol. 2006 Feb 20;24(6):929-36
references: 16432076
references: Br J Haematol. 2005 Aug;130(4):588-94
references: 16098074
references: Cancer. 2004 Jun 15;100(12):2607-12
references: 15197803
references: Blood. 2010 Jan 7;115(1):32-7
references: 19884643
references: Blood. 1998 Nov 1;92(9):3131-6
references: 9787148
references: N Engl J Med. 2003 Dec 25;349(26):2495-502
references: 14695409
references: Blood. 2006 Nov 15;108(10):3289-94
references: 16873668
references: Leukemia. 2006 Feb;20(2):345-9
references: 16319952
references: Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54
references: 18022574
references: J Clin Oncol. 2007 Jun 10;25(17):2434-41
references: 17485707
references: N Engl J Med. 2003 May 8;348(19):1875-83
references: 12736280